litlas
ログインアカウント作成

Paul D. Miller

1967–2024 年に発表

156
論文数
36,426
被引用数
104
h 指数
153
i10 指数

被引用数

Paul D. Miller の年別被引用数1961 年: 被引用 1 件1977 年: 被引用 1 件1978 年: 被引用 3 件1979 年: 被引用 2 件1980 年: 被引用 7 件1981 年: 被引用 8 件1982 年: 被引用 5 件1983 年: 被引用 6 件1984 年: 被引用 14 件1985 年: 被引用 9 件1986 年: 被引用 7 件1987 年: 被引用 15 件1988 年: 被引用 13 件1989 年: 被引用 4 件1990 年: 被引用 4 件1991 年: 被引用 8 件1992 年: 被引用 7 件1993 年: 被引用 9 件1994 年: 被引用 11 件1995 年: 被引用 18 件1996 年: 被引用 34 件1997 年: 被引用 33 件1998 年: 被引用 32 件1999 年: 被引用 31 件2000 年: 被引用 59 件2001 年: 被引用 92 件2002 年: 被引用 183 件2003 年: 被引用 183 件2004 年: 被引用 215 件2005 年: 被引用 191 件2006 年: 被引用 295 件2007 年: 被引用 229 件2008 年: 被引用 329 件2009 年: 被引用 268 件2010 年: 被引用 306 件2011 年: 被引用 277 件2012 年: 被引用 237 件2013 年: 被引用 216 件2014 年: 被引用 212 件2015 年: 被引用 206 件2016 年: 被引用 209 件2017 年: 被引用 261 件2018 年: 被引用 245 件2019 年: 被引用 744 件2020 年: 被引用 961 件2021 年: 被引用 781 件2022 年: 被引用 600 件2023 年: 被引用 423 件2024 年: 被引用 753 件2025 年: 被引用 327 件2026 年: 被引用 3 件1962〜1976 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,362 件、この内訳の 25%イギリス: 引用元論文 776 件、この内訳の 8.2%中国: 引用元論文 642 件、この内訳の 6.8%カナダ: 引用元論文 504 件、この内訳の 5.3%イタリア: 引用元論文 417 件、この内訳の 4.4%オーストラリア: 引用元論文 408 件、この内訳の 4.3%フランス: 引用元論文 354 件、この内訳の 3.7%ドイツ: 引用元論文 347 件、この内訳の 3.7%スイス: 引用元論文 322 件、この内訳の 3.4%ベルギー: 引用元論文 313 件、この内訳の 3.3%日本: 引用元論文 272 件、この内訳の 2.9%オランダ: 引用元論文 269 件、この内訳の 2.8%
0%25%その他 26.2%

機関

分野

  • Medicine80.5%
  • Biochemistry, Genetics and Molecular Biology12.7%
  • Engineering1.5%
  • Health Professions0.7%
  • Immunology and Microbiology0.6%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • その他3.5%

トピック

  • Bone health and osteoporosis research20.4%
  • Bone health and treatments11.6%
  • Bone Metabolism and Diseases8.9%
  • Bone and Joint Diseases4.9%
  • Hip and Femur Fractures4.4%
  • Parathyroid Disorders and Treatments4%
  • その他45.8%

共著者

全論文

検索で開く
  1. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis — 2016-Executive Summary

    著者: Pauline M. Camacho, Steven M. Petak, Neil Binkley, B.L. Clarke, Steven T. Harris, Daniel L. Hurley, Michael Kleerekoper, E. Michael Lewiecki, Paul D. Miller, Harmeet S. Narula, Rachel Pessah‐Pollack, Vin Tangpricha, Sunil J. Wimalawansa, Nelson B. Watts - Endocrine Practice 2016 被引用: 1,144

  2. Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis

    著者: Paul D. Miller, Gary Hattersley, Bente Juel Riis, Gregory C. Williams, Edith Lau, Luis Augusto Tavares Russo, Peter Alexandersen, Cristiano A. F. Zerbini, Ming‐yi Hu, Alan G. Harris, Lorraine A. Fitzpatrick, Felicia Cosman, Claus Christiansen, for the ACTIVE Study Investigators - JAMA 2016 被引用: 847

  3. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis

    著者: E. Michael Lewiecki, Tomasz Blicharski, Stefan Goemaere, Kurt Lippuner, Paul Meisner, Paul D. Miller, Akimitsu Miyauchi, Judy Maddox, Li Chen, S. Horlait - The Journal of Clinical Endocrinology & Metabolism 2018 被引用: 317

  4. Bone Mineral Density Thresholds for Pharmacological Intervention to Prevent Fractures

    著者: Ethel S. Siris, Ya-Ting Chen, Thomas A. Abbott, Elizabeth Barrett‐Connor, Paul D. Miller, Lois E. Wehren, Marc L. Berger - Archives of Internal Medicine 2004 被引用: 1,083

  5. Effects of Denosumab Treatment and Discontinuation on Bone Mineral Density and Bone Turnover Markers in Postmenopausal Women with Low Bone Mass

    著者: Henry G. Bone, Michael A. Bolognese, Chui Kin Yuen, David L. Kendler, Paul D. Miller, YuChing Yang, Luanda Grazette, Javier San Martín, John C. Gallagher - The Journal of Clinical Endocrinology & Metabolism 2011 被引用: 611

  6. ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

    著者: Henry G. Bone, Felicia Cosman, Paul D. Miller, Gregory C. Williams, Gary Hattersley, Ming‐yi Hu, Lorraine A. Fitzpatrick, Bruce Mitlak, Socrates E. Papapoulos, René Rizzoli, Robin K. Dore, John P. Bilezikian, Kenneth G. Saag - The Journal of Clinical Endocrinology & Metabolism 2018 被引用: 201

  7. Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis

    著者: Harry K. Genant, Cyrus Cooper, Gyula Poór, Ian Reid, George E. Ehrlich, J. A. Kanis, B. E. C. Nordin, Elizabeth Barrett‐Connor, Dennis M. Black, Jean‐Philippe Bonjour, Bess Dawson‐Hughes, P.D. Delmas, J. Dequeker, Sérgio Ragi Eis, C. Gennari, O Johnell, C. Conrad Johnston, E. M. C. Lau, Uri Liberman, Robert S. Lindsay, T. John Martin, Basel Masri, C. Mautalén, Pierre J. Meunier, Paul D. Miller, Ambrish Mithal, Hirotoshi Morii, Socrates E. Papapoulos, Anthony D. Woolf, Wei Yu, Nikolai Khaltaev - Osteoporosis International 1999 被引用: 786

  8. Osteoporosis and Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD): Back to Basics

    著者: Michael Pazianas, Paul D. Miller - American Journal of Kidney Diseases 2021 被引用: 154

  9. Denosumab in Postmenopausal Women with Low Bone Mineral Density

    著者: Michael R. McClung, E. Michael Lewiecki, Stanley Cohen, Michael A. Bolognese, Grattan C. Woodson, Alfred H. Moffett, Munro Peacock, Paul D. Miller, Samuel Lederman, Charles H. Chesnut, Douglas Lain, Alan Kivitz, Donna Holloway, Charlie Zhang, Mark Peterson, Pirow Bekker - New England Journal of Medicine 2006 被引用: 1,215

  10. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

    著者: Paul D. Miller, Nicola Pannacciulli, Jacques P. Brown, E. J. Czerwiński, Bettina S. Nedergaard, Michael A. Bolognese, Jorge Malouf, Henry G. Bone, Jean‐Yves Reginster, Andrea Singer, C. Wang, Rachel B. Wagman, Steven R. Cummings - The Journal of Clinical Endocrinology & Metabolism 2016 被引用: 234

  11. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease

    著者: Paul D. Miller, Jonathan D. Adachi, Ben‐Hur Albergaria, Angela M. Cheung, Arkadi Chines, Evelien Gielen, Bente Langdahl, Akimitsu Miyauchi, Mary Oates, Ian R. Reid, Norma Ruiz Santiago, Mark Vanderkelen, Zhenxun Wang, Zhigang Yu - Journal of Bone and Mineral Research 2020 被引用: 93

  12. Identification and Fracture Outcomes of Undiagnosed Low Bone Mineral Density in Postmenopausal Women

    著者: Ethel S. Siris, Paul D. Miller, Elizabeth Barrett‐Connor, Kenneth G. Faulkner, Lois E. Wehren, Thomas A. Abbott, Marc L. Berger, Arthur C. Santora, Louis M. Sherwood - JAMA 2001 被引用: 1,220

  13. Effects of denosumab on fracture and bone mineral density by level of kidney function

    著者: Sophie A. Jamal, Östen Ljunggren, Catherine Stehman‐Breen, Steven R. Cummings, Michael R. McClung, Stefan Goemaere, Peter R. Ebeling, Edward Franek, YuChing Yang, Ogo Egbuna, Steven Boonen, Paul D. Miller - Journal of Bone and Mineral Research 2011 被引用: 352

  14. Effect of Risedronate on the Risk of Hip Fracture in Elderly Women

    著者: Michael R. McClung, Piet Geusens, Paul D. Miller, H Zippel, W. Bensen, Christian Roux, Silvano Adami, Ignac Fogelman, Terrence Diamond, Richard Eastell, Pierre J. Meunier, Richard D. Wasnich, Maria Greenwald, Jean‐Marc Kaufman, Charles H. Chesnut, Jean‐Yves Reginster - New England Journal of Medicine 2001 被引用: 1,926

  15. Management of severe osteoporosis

    著者: Paul D. Miller - Expert Opinion on Pharmacotherapy 2015 被引用: 193

  16. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis

    著者: Felicia Cosman, Erik Fink Eriksen, Chris Recknor, Paul D. Miller, Núria Guañabens, Christian Kasperk, P. Papanastasiou, Aimee Readie, Hanumantha Rao, Jürg A. Gasser, Christina Bucci‐Rechtweg, Steven Boonen - Journal of Bone and Mineral Research 2010 被引用: 359

  17. Bisphosphonate Therapy for Osteoporosis: Benefits, Risks, and Drug Holiday

    著者: Michael R. McClung, Steven T. Harris, Paul D. Miller, Douglas C. Bauer, K. Shawn Davison, Larry Dian, David A. Hanley, David L. Kendler, Chui Kin Yuen, E. Michael Lewiecki - The American Journal of Medicine 2012 被引用: 453

  18. Benefits and Risks of Bisphosphonate Therapy for Osteoporosis

    著者: Sundeep Khosla, John P. Bilezikian, David W. Dempster, E. Michael Lewiecki, Paul D. Miller, Robert M. Neer, Robert R. Recker, Elizabeth Shane, Dolores Shoback, John T. Potts - The Journal of Clinical Endocrinology & Metabolism 2012 被引用: 285

  19. Observations following discontinuation of long-term denosumab therapy

    著者: Michael R. McClung, R.B. Wagman, Paul D. Miller, A. Wang, E. Michael Lewiecki - Osteoporosis International 2017 被引用: 220

  20. Underdiagnoses and Undertreatment of Osteoporosis: The Battle to Be Won

    著者: Paul D. Miller - The Journal of Clinical Endocrinology & Metabolism 2016 被引用: 116

  21. Vertebral Fractures: Clinical Importance and Management

    著者: David L. Kendler, Douglas C. Bauer, K. Shawn Davison, Larry Dian, David A. Hanley, S. T. Harris, Michael R. McClung, Paul D. Miller, John T. Schousboe, Chui Kin Yuen, E. Michael Lewiecki - The American Journal of Medicine 2015 被引用: 315

  22. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment

    著者: Paul D. Miller, Elliott N. Schwartz, P. Chen, Derek Misurski, John H. Krege - Osteoporosis International 2006 被引用: 236

  23. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use

    著者: Anthony B. Hodsman, Douglas C. Bauer, David W. Dempster, Larry Dian, David A. Hanley, Steven T. Harris, David L. Kendler, Michael R. McClung, Paul D. Miller, Wojciech P. Olszynski, Eric Orwoll, Chui Kin Yuen - Endocrine Reviews 2005 被引用: 721

  24. Osteoporosis and Fracture Risk in Women of Different Ethnic Groups

    著者: Elizabeth Barrett‐Connor, Ethel S. Siris, Lois E. Wehren, Paul D. Miller, Thomas A. Abbott, Marc L. Berger, Arthur C. Santora, Louis M. Sherwood - Journal of Bone and Mineral Research 2005 被引用: 557